TP53 and prostate carcinoma: Approximately 26% of primary prostate cancers appear to be driven by occult molecular abnormalities or by one or more frequent alterations that co-occur with the genomically defined classes; a part of these tumors is characterized by a high burden of SCNAs or DNA hypermethylation; furthermore, these tumors were enriched for mutations in TP53, KDM6A, KMT2D, deletions of chromosomes 6 and 1b, and amplifications of chromosomes 8 and 11 [38].